BioVeris Corporation engages in the development, manufacture, and marketing of diagnostic products for the detection and measurement of biological and chemical substances. It offers M-SERIES clinical diagnostics analyzer and tests for Screening, monitoring, and diagnosing medical conditions; M384 analyzer, reagents, biomarkers, and antibody panels, as well as M1M Analyzer, reagents, biomarkers, and antibody panels for drug discovery and development; M1M analyzer and reagents for detection of food and beverage contaminants and bacteria, viruses, and toxins; and Cell culture reagents for biological research. The company also sells M-SERIES instruments for life science research to pharmaceutical and biotechnology researchers, as well as to scientists at academic and government research institutions. In addition, BioVeris develops vaccines for various diseases, including meningococcal, group A and group B streptococcus, chlamydia, candida albicans, pneumococcus, anthrax, and urinary tract infection. The company offers its products to various government agencies in the biosecurity market, food and beverage producers, and contract testing laboratories in the industrial market, as well as other customers in the life science market. It sells its products through direct sales force and distributors in the United States and Europe. The company, formerly known as IGEN Integrated Healthcare, LLC, was founded in 2003 and is based in Gaithersburg, Maryland. As of June 26, 2007, BioVeris Corp. is a subsidiary of Roche Holding AG.